A detailed history of Freestone Capital Holdings, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Freestone Capital Holdings, LLC holds 18,020 shares of RVNC stock, worth $46,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,020
Holding current value
$46,311
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.57 - $2.57 $46,311 - $46,311
18,020 New
18,020 $46,000
Q4 2022

Feb 13, 2023

SELL
$18.32 - $30.66 $224,163 - $375,155
-12,236 Reduced 40.44%
18,020 $332,000
Q2 2022

Aug 09, 2022

BUY
$11.52 - $20.4 $6,900 - $12,219
599 Added 2.02%
30,256 $418,000
Q4 2021

Feb 14, 2022

BUY
$12.46 - $27.87 $4,772 - $10,674
383 Added 1.31%
29,657 $484,000
Q4 2020

Feb 16, 2021

BUY
$23.41 - $28.34 $685,304 - $829,625
29,274 New
29,274 $830 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Freestone Capital Holdings, LLC Portfolio

Follow Freestone Capital Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Capital Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Capital Holdings, LLC with notifications on news.